We are live on ! Find out more
TBIO

Translate Bio, Inc. Common Stock
TBIO

Delisted

TBIO was delisted on the 13th of September, 2021.

52 hedge funds and large institutions have $299M invested in Translate Bio, Inc. Common Stock in 2019 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 25 increasing their positions, 5 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

400% more repeat investments, than reductions

Existing positions increased: 25 | Existing positions reduced: 5

83% more first-time investments, than exits

New positions opened: 11 | Existing positions closed: 6

50% more capital invested

Capital invested by funds: $200M → $299M (+$99.2M)

11% more funds holding

Funds holding: 4752 (+5)

0% more funds holding in top 10

Funds holding in top 10: 22 (0)

Holders
52
Holders Change
+5
Holders Change %
+10.64%
% of All Funds
1.12%
Holding in Top 10
2
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.04%
New
11
Increased
25
Reduced
5
Closed
6
Calls
Puts
Net Calls
Net Calls Change

TBIO Hedge Fund Activity: Q1 2019 in Review

52 of the 4,633 institutional investors tracked by Wall St. Rank reported a position in Translate Bio, Inc. Common Stock (TBIO) for Q1 2019, worth a combined $299M — up 50% from $200M a quarter earlier.

Buyers outnumbered sellers: 11 funds opened new TBIO positions and 6 closed out — a net gain of 5 holders — while 25 added to existing stakes and 5 trimmed.

The largest buyer was RTW Investments, opening a new position worth an estimated $10.4M. The largest seller was Farallon Capital Management, cutting an estimated $3.07M.

  • 52 institutional investors held Translate Bio, Inc. Common Stock (TBIO) as of Q1 2019, up from 47 in Q4 2018.
  • Funds reported $299M of Translate Bio, Inc. Common Stock stock for Q1 2019, up 50% quarter-over-quarter.
  • 11 funds opened new Translate Bio, Inc. Common Stock positions in Q1 2019 and 6 closed out, a net change of +5 holders.
  • The largest Translate Bio, Inc. Common Stock buyer in Q1 2019 was RTW Investments, an estimated $10.4M added.
  • The largest Translate Bio, Inc. Common Stock seller in Q1 2019 was Farallon Capital Management, an estimated $3.07M sold.

Based on aggregated 13F filings for Q1 2019.